Core Viewpoint - WuXi AppTec (药明康德) is actively reducing its stake in WuXi AppTec Holdings (药明合联) through multiple transactions, raising significant cash for strategic investments while experiencing a decline in R&D expenses and workforce [2][3][6]. Group 1: Share Reduction and Financial Impact - WuXi AppTec has sold 30.3 million shares of WuXi AppTec Holdings, representing 2.47% of its total share capital, for approximately HKD 23.46 billion [3]. - Over the past year, the company has cumulatively reduced its holdings in WuXi AppTec Holdings, generating HKD 69.5 billion (approximately RMB 63.72 billion) [6]. - The sale of shares is expected to impact the company's net profit for 2025 by approximately RMB 16.79 billion, which is over 10% of the latest audited net profit attributable to shareholders [4]. Group 2: R&D Expenses and Workforce Changes - WuXi AppTec's R&D expenses have been declining for two and a half years, totaling RMB 31.94 billion, which is only 3.18% of the total revenue of RMB 1003.81 billion during the same period [11]. - The company has seen a significant reduction in its workforce, with a total decrease of 6,529 employees, or 14.72%, from the end of 2022 to mid-2025 [12]. - Despite the workforce reduction, executive compensation remains high, with the CEO receiving a total of RMB 126 million over three years [13]. Group 3: Revenue Performance and Global Strategy - In 2022, WuXi AppTec reported revenue of RMB 393.55 billion, with a year-on-year growth of 71.84%, and net profit of RMB 88.14 billion, also up 72.91% [7]. - The company anticipates a return to double-digit revenue growth in 2025, adjusting its revenue forecast to between RMB 425 billion and RMB 435 billion [11]. - As of mid-2025, the company has a backlog of orders worth RMB 566.9 billion, reflecting a year-on-year increase of 37.2%, with significant contributions from U.S. and European clients [12].

Core Viewpoint - WuXi AppTec is continuously reducing its stake in WuXi AppTec Holdings, having sold 30.3 million shares recently for approximately HKD 23.46 billion, which represents 2.47% of the total share capital of WuXi AppTec Holdings [2][4] Share Reduction and Financial Impact - Over the past year, WuXi AppTec has cumulatively reduced its holdings in WuXi AppTec Holdings, realizing approximately HKD 69.5 billion, equivalent to RMB 63.72 billion [2][7] - The recent sale is part of a strategy to accelerate global capacity and capability building, aiming to attract and retain talent while enhancing its integrated CRDMO business model [4][17] - The net investment gain from the recent sale is expected to impact the company's net profit for 2025 by approximately RMB 16.79 billion, accounting for over 10% of the latest audited net profit attributable to shareholders [4][5] R&D Expenditure Trends - WuXi AppTec's R&D expenses have been declining for two and a half years, totaling RMB 31.94 billion, which is only 3.18% of the total revenue of RMB 1003.81 billion during the same period [10][12] - R&D expenses for 2023 and 2024 were RMB 14.41 billion and RMB 12.39 billion, respectively, showing a decline of over 10% each year [10][12] - The company reported a significant drop in R&D expenses in the first half of 2025, amounting to RMB 5.14 billion, which is a 19.15% decrease year-on-year [12] Employee Reduction - WuXi AppTec has reduced its workforce by 6,529 employees over two and a half years, representing a 14.72% decrease [13][14] - Employee numbers decreased from 44,361 at the end of 2022 to 37,832 by mid-2025 [13][14] Executive Compensation - Despite workforce reductions, executive compensation remains high, with the chairman and CEO receiving a total of RMB 126 million over three years [15][16] Business Performance and Global Strategy - WuXi AppTec's revenue for the first half of 2025 reached RMB 207.99 billion, a year-on-year increase of 20.64%, with net profit growing by 101.92% [11] - The company is focusing on global expansion, with a backlog of orders amounting to RMB 566.9 billion, a 37.2% increase year-on-year [17]